Search Results

You are looking at 91 - 100 of 202 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Philippe E. Spiess

node dissection (ILND) is recommended, and again DSNB is a category 2B recommendation. “We are somewhat cautious in promoting this type of technique [DSNB],” admitted Dr. Spiess. For those with more aggressive primary tumor, the gold standard remains

Full access

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru, and Saby George

. Therefore, chemotherapy was discontinued and she underwent a robot-assisted radical cystectomy with open construction of an ileal neobladder and an extended bilateral pelvic lymph node dissection. Figure 1 CT scan showing irregular necrotic mass at

Full access

Srinivas K. Tantravahi, and Theresa L. Werner

management of early-stage tumors and treatment failure with isolated local recurrence. In medically operable patients, total hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymph node dissection is the recommended surgery for

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

have a 2.7-cm moderately differentiated invasive ductal carcinoma that was estrogen receptor–positive/progesterone receptor–positive/HER2-positive (ER+/PR+/HER2+) on immunohistochemistry. Lymph node dissection was negative in 0 of 23 nodes. Surgical

Full access

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

after gastrectomy for gastric cancer: data from a large US-population database . J Clin Oncol 2005 ; 23 : 7114 – 7124 . 21. Bonenkamp JJ Hermans J Sasako M . Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

management strategy for stage I TC. 14 For stage I nonseminoma, adjuvant chemotherapy with 1 cycle of bleomycin/etoposide/cisplatin (BEPX1) and retroperitoneal lymph node dissection (RPLND) are other options, whereas adjuvant chemotherapy with 1 cycle of

Full access

Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

—this, according to Dr. Bishop, was enough of a response to render the tumor resectable. Sixteen lymph nodes were removed during axillary lymph node dissection and were negative for any viable metastatic carcinoma, resulting in a pathologic CR. According to Dr

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

regional lymph node dissection following the corresponding pathway for the head and neck region (see page 845) or the trunk and extremity region (see page 846). Radiation alone is an alternative when surgery is not initially feasible; however, after

Full access

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

as long as the patient has no contraindications to this treatment. Lymphadenectomy The extent of lymph node dissection needed during radical cystectomy for MIBC is controversial. 8 Data show that a more extensive lymph node dissection may

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate